Skip to main content

Table 2 Univariate, multivariate cox proportional hazards regression in the PSM cohort. (n = 220)

From: Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage

 Overall survivalDisease-free survival
univariatemultivariateunivariatemultivariate
HR(95%CI)p valueHR(95%CI)p valueHR(95%CI)p valueHR(95%CI)p value
Treatment
 S-11     1     
 XELOX0.710.40–1.260.240   0.650.39–1.090.101   
Age (years)
  < 651  1  1     
  ≥ 651.931.11–3.350.021.330.72–2.460.3631.580.96–2.600.07   
Sex
 Female1     1     
 Male1.140.64–2.040.66   1.250.85–2.110.393   
ECOG
 01  1  1  1  
  ≥ 12.321.31–4.1201.540.80–3.000.1982.171.28–3.6601.720.99–2.980.051
ASA
 1 to 21     1     
  ≥ 30.850.58–1.260.420   1.10.85–1.430.462   
Location
 Other1     1     
 EGJ0.540.13–2.230.398   2.820.88–9.010.081   
T stage
 T1,T21     1     
 T3,T43.190.78–13.120.108   2.650.83–8.470.1   
N stage
 N0,1,211 1  1  1  
 N31.691.37–2.09< 0.0011.41.09–1.800.0091.541.29–1.84< 0.0011.261.00–1.580.05
LNR group
 LNR0,1,21  1  1  1  
 LNR31.71.41–2.04< 0.0011.361.09–1.700.0061.671.41–1.97< 0.0011.441.16–1.780
Tumor size
  < 61  1  1  1  
  ≥ 61.951.13–3.390.021.070.97–1.180.2091.911.16–3.130.011.0490.96–1.150.288
Differntiation
 Well to moderately1     1     
 Poorly0.810.44–1.510.512   0.950.53–1.690.855   
Lauren classification
 Intestinal1     1     
 Diffuse/Mixed0.940.70–1.260.681   0.990.75–1.300.923   
Lymphovascular invasion
 no1     1     
 yes3.130.76–12.880.114   2.530.79–8.070.117   
Perineural invasion
 no1  1  1  1  
 yes2.721.36–5.430.012.391.18–4.820.0152.051.15–3.660.021.470.81–2.660.205
Chemotherapy completion
 no1  1  1  1  
 yes0.430.24–0.7700.50.28–0.910.0230.360.21–0.59< 0.0010.360.21–0.61< 0.001
CEA (before surgery)
 normal1     1     
 elevated1.310.32–5.380.711   1.020.25–4.190.975   
CEA (after surgery)
 normal1     1     
 elevated1.140.28–4.680.86   0.910.22–3.740.902   
CA 19–9 (before surgery)
 normal1     1  1  
 elevated1.870.84–4.160.123   2.661.36–5.240.011.810.88–3.740.107
CA 19–9 (after surgery)
 normal1     1     
 elevated1.320.32–5.410.705   2.090.65–6.670.213   
  1. Univariate analysis and multivariate survival analysis were performed using Cox proportional hazard model, and P values < 0.05 were considered to indicate statistical significance
  2. Abbreviations: CI confidence interval, HR hazard ratio. Significant values are in boldface type